Skip to main content
$16.19 $0.29 (1.8%)

01:08 PM EDT on 09/28/22

Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 4 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Current Price $16.19 Mkt Cap $5.1B
Open $16.10 P/E Ratio 16.89
Prev. Close $15.90 Div. (Yield) $0.00 (0.0%)
Daily Range $16.02 - $16.35 Volume 773,657
52-Wk Range $15.50 - $23.40 Avg. Daily Vol. 2,108,509

Caps

How do you think NASDAQ:EXEL will perform against the market?

Add Stock to CAPS Watchlist

All Players

2,438 Outperform
95 Underperform
 

All-Star Players

423 Outperform
26 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:EXEL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Car12703 (< 20)
Submitted November 10, 2021

From Fidelity or Zacks November 2021:Revenue Growth (Last 5 Years) = 92.7%Revenue % Change (Last Qrtr VS. Same Qrtr Prior Year) = 42.1%Price/Sales (TTM) = 5.2

BRADYstocks (24.53)
Submitted February 26, 2008

This sector is a scary one! Fear, though, is a fools game. I don't expect this stock to move upwards in the very near future. The cash burn is, well, similar to that Texas A&M bonfire tradition.

Recent Community Commentary

Read the most recent pitches from players about EXEL.

Recs

0
Member Avatar TMFjimhalley (< 20) Submitted: 2/25/2022 2:23:42 PM : Outperform Start Price: $19.68 NASDAQ:EXEL Score: -1.68

Strong revenue growth and a oncology portfolio that is growing.

Recs

1
Member Avatar Car12703 (< 20) Submitted: 11/10/2021 6:26:58 AM : Outperform Start Price: $18.41 NASDAQ:EXEL Score: +9.11

From Fidelity or Zacks November 2021:
Revenue Growth (Last 5 Years) = 92.7%
Revenue % Change (Last Qrtr VS. Same Qrtr Prior Year) = 42.1%
Price/Sales (TTM) = 5.2

Recs

2
Member Avatar MrUrban (< 20) Submitted: 7/24/2020 8:04:22 PM : Outperform Start Price: $24.73 NASDAQ:EXEL Score: -48.87

First one i picked all by myself, reason:
1. Mkt Cap 7.39B plenty place to grow
2. EPS nxt Yr 94.84%
3.EPS nxt 5Yr 46.00%
4. Sales past 5Yr 107.60%
5. Dept/ Equity 0

Issues:
1. High insider transactions almost 30%
2. Company works on cure for cancer - high volatility
3. EPS this Y -53.80% but justified by Covid-19

Practice and enjoy!

Leaderboard

Find the members with the highest scoring picks in EXEL.

Score Leader

LMNOPQRStallion

LMNOPQRStallion (< 20) Score: +1,135.30

The Score Leader is the player with the highest score across all their picks in EXEL.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Playa14 < 20 12/26/2014 12/5/2019 Outperform 5Y $1.27 +1,179.53% +76.91% +1,102.61 0 Comment
beave35 90.35 12/23/2014 Outperform 5Y $1.30 +1,149.90% +77.19% +1,072.72 0 Comment
tomkao < 20 12/15/2014 Outperform 5Y $1.40 +1,060.71% +82.82% +977.89 0 Comment
jack0071 65.80 12/3/2014 Outperform 5Y $1.43 +1,036.36% +77.78% +958.59 0 Comment
portefeuille 98.21 12/15/2014 5/31/2021 Outperform NS $1.44 +1,028.47% +82.46% +946.01 0 Comment
akoniec 22.86 10/9/2014 Outperform 3Y $1.55 +948.39% +87.71% +860.68 0 Comment
dcoyne13 43.40 9/16/2014 Outperform 5Y $1.62 +903.02% +84.36% +818.67 0 Comment
foolerhoff 65.32 1/6/2015 Outperform 5Y $1.64 +890.85% +82.36% +808.49 0 Comment
garisonmp3z < 20 1/5/2015 Outperform 5Y $1.67 +873.05% +80.50% +792.55 0 Comment
new2fool23 53.09 1/5/2015 Outperform 1Y $1.67 +873.05% +80.50% +792.55 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for EXEL.